Bavencio; INN-Avelumab

Bavencio; INN-Avelumab

10 December 2020 EMA/CHMP/3166/2021 Committee for Medicinal Products for Human Use (CHMP) Assessment report Bavencio International non-proprietary name: avelumab Procedure No. EMEA/H/C/004338/II/0018 Note Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us An agency of the European Union Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 7 1.1. Type II variation ................................................................................................ 7 1.2. Steps taken for the assessment of the product ....................................................... 8 2. Scientific discussion ................................................................................ 9 2.1. Introduction ...................................................................................................... 9 2.1.1. Problem statement .......................................................................................... 9 2.1.2. About the product ........................................................................................... 9 2.1.3. The development programme/compliance with CHMP guidance/scientific advice ..... 10 2.1.4. General comments on compliance with GCP ...................................................... 10 2.2. Non-clinical aspects .......................................................................................... 10 2.2.1. Ecotoxicity/environmental risk assessment ........................................................ 10 2.3. Clinical aspects ................................................................................................ 11 2.3.1. Introduction ................................................................................................. 11 2.3.2. Pharmacokinetics .......................................................................................... 12 2.3.3. Pharmacodynamics ........................................................................................ 30 2.3.4. PK/PD modelling............................................................................................ 30 2.3.5. Discussion on clinical pharmacology ................................................................. 36 2.3.6. Conclusions on clinical pharmacology ............................................................... 37 2.4. Clinical efficacy ................................................................................................ 38 2.4.1. Main study ................................................................................................... 38 2.4.2. Discussion on clinical efficacy .......................................................................... 94 2.4.3. Conclusions on the clinical efficacy ................................................................... 97 2.5. Clinical safety .................................................................................................. 97 2.5.1. Discussion on clinical safety ........................................................................... 134 2.5.2. Conclusions on clinical safety ......................................................................... 136 2.5.3. PSUR cycle .................................................................................................. 136 2.6. Risk management plan ..................................................................................... 136 2.7. Update of the Product information ..................................................................... 149 2.7.1. User consultation.......................................................................................... 149 2.7.2. Additional monitoring .................................................................................... 149 3. Benefit-Risk Balance............................................................................ 149 3.1. Therapeutic Context ........................................................................................ 149 3.1.1. Disease or condition...................................................................................... 149 3.1.2. Available therapies and unmet medical need .................................................... 150 3.1.3. Main clinical studies ...................................................................................... 150 3.2. Favourable effects ........................................................................................... 150 3.3. Uncertainties and limitations about favourable effects .......................................... 151 3.4. Unfavourable effects ........................................................................................ 151 3.5. Uncertainties and limitations about unfavourable effects ....................................... 152 3.6. Effects Table .................................................................................................. 152 3.7. Benefit-risk assessment and discussion .............................................................. 153 3.7.1. Importance of favourable and unfavourable effects ........................................... 153 3.7.2. Balance of benefits and risks .......................................................................... 153 Assessment report EMA/CHMP/3166/2021 Page 2/154 3.7.3. Additional considerations on the benefit-risk balance ......................................... 153 3.8. Conclusions .................................................................................................... 153 4. Recommendations ............................................................................... 154 5. EPAR changes ...................................................................................... 154 Assessment report EMA/CHMP/3166/2021 Page 3/154 List of abbreviations Abbreviation Term ADA anti-drug antibody ADCC antibody-dependent cell-mediated cytotoxicity ADR adverse drug reaction AE adverse event aRCC advanced renal cell carcinoma aUC locally advanced or metastatic urothelial carcinoma BICR blinded independent central review BLA Biologics License Application BOR best overall response BSC best supportive care BTD Breakthrough Designation CHMP Committee for Medicinal Products for Human Use CI confidence interval CL total systemic clearance CPK creatinine phosphokinase CO Clinical Overview CR complete response CSR Clinical Study Report Ctrough predose concentration CV coefficient of variation eCRF electronic case report form DR duration of response DRS-P Disease Related Symptoms – Physical ECG electrocardiogram ECOG Eastern Cooperative Oncology Group EMA European Medicines Agency EQ-5D-5L EuroQol 5 dimensions 5 levels ESMO European Society for Medical Oncology EU European Union FACT Functional Assessment of Cancer Therapy Assessment report EMA/CHMP/3166/2021 Page 4/154 FBlSI-18 FACT Bladder Symptom Index FDA Food and Drug Administration GCP Good Clinical Practice GGT gamma-glutamyl transferase GMP Good Manufacturing Practice HR hazard ratio ICH International Conference for Harmonisation IHC immunohistochemistry Ig Immunoglobulin IND Investigational New Drug IR Incident Rate per 100 patient months irAE immune-related adverse event IRR infusion related reaction ISS Integrated Summary of Safety IV intravenous LLQ lower limit of quantification mAb monoclonal antibody MAH Marketing Authorisation Holder MCC Merkel cell carcinoma nAb neutralizing antibody NCCN National Comprehensive Cancer Network NCI CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events NE not evaluable OR(R) objective response (rate) OS overall survival PBRER Periodic Benefit-Risk Evaluation Report PD progressive disease PD-1 programmed cell death protein 1 PD-L1 programmed cell death protein-ligand 1 PFS progression-free survival PIPD potentially important protocol deviation PK pharmacokinetics Assessment report EMA/CHMP/3166/2021 Page 5/154 PM Patient Months of Exposure PMAR Population Modelling Analysis Report popPK population pharmacokinetics PR partial response PRO patient-reported outcomes PT preferred term Q2W every 2 weeks RCC renal cell carcinoma RCI repeated confidence interval RECIST v1.1 Response Evaluation Criteria in Solid Tumours Version 1.1 RTOR Real Time Oncology Review SAP statistical analysis plan SAE serious adverse event SBS Summary of Biopharmaceutics and Associated Analytical Methods sBLA Supplemental Biologics License Application SCE Summary of Clinical Efficacy SCP Summary of Clinical Pharmacology Studies SCS Summary of Clinical Safety SD stable disease SmPC Summary of Product Characteristics TKI tyrosine kinase inhibitor TEAE treatment-emergent adverse event TTD time to deterioration UC urothelial carcinoma US United States VEGFR vascular endothelial growth factor receptor Assessment report EMA/CHMP/3166/2021 Page 6/154 1. Background information on the procedure 1.1. Type II variation Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Merck Europe B.V. submitted to the European Medicines Agency on 26 May 2020 an application for a variation. The following variation was requested: Variation requested Type Annexes affected C.I.6.a C.I.6.a - Change(s) to therapeutic indication(s) - Addition

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    154 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us